Previous 10 |
Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...
- BELLUS to own 100% of BLU-5937 and related P2X3 antagonists intellectual property with no future payments due - - 4.77 million BELLUS Health common shares to be issued in consideration - BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS He...
BELLUS Health ( BLU ) has completed patient enrollment for the RELIEF trial , its dose-escalation Phase 2 study of BLU-5937 in patients with refractory chronic cough. More news on: BELLUS Health, Healthcare stocks news, Read more ...
- On track to report topline data from the RELIEF trial in mid-2020 - BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and...
BELLUS Health ( BLU ): FY GAAP EPS of -C$0.73. More news on: BELLUS Health, Earnings news and commentary, Healthcare stocks news, , Read more ...
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial a...
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto B...
News, Short Squeeze, Breakout and More Instantly...
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON , June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed ...
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced the positive outcome of the BELLUS shareholders (“ Shareholders ”) vote at this morning’s special meeting of the Shareholders (the “ ...
Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding o...